ĐIỀU TRỊ THUỐC HẠ LIPID MÁU THEO KHUYẾN CÁO TRÊN NGƯỜI BỆNH ĐÁI THÁO ĐƯỜNG TYPE 2 MỚI CHẨN ĐOÁN

Abstract

Introduction: Type 2 diabetes is a significant cardiovascular risk factor. In addition to stabilizing blood glucose, managing other risk factors such as dyslipidemia, particularly LDL cholesterol, is essential to prevent the development and progression of cardiovascular complications. Initiating guideline-directed lipid-lowering treatment at diagnosis effectively controls LDL cholesterol and improves patient prognosis. Objective: This study aimed to determine the prescription rate of lipid-lowering medications according to current guidelines in newly diagnosed type 2 diabetes patients. Methods: A descriptive cross-sectional study was conducted on type 2 diabetes patients diagnosed within the past six months at the Endocrinology and Family Medicine clinics of the University Medical Center, Ho Chi Minh City. Prescriptions were recorded at the time of the patient’s visit, and adherence to lipid-lowering treatment guidelines was evaluated based on the 2020 treatment guidelines of the Ministry of Health of Vietnam. Results: 275 newly diagnosed type 2 diabetes patients were enrolled in the study. The prevalence of comorbid dyslipidemia was 81,8%. Cardiovascular risk stratification included 3,6% at moderate risk, 53,1% at high risk, and 43,3% at very high risk. Most patients (62,9%) were prescribed statins, 22,5% received a combination of statin and ezetimibe, 12,8% received fibrate monotherapy, and 1,5% were prescribed a combination of statin and fibrate. The proportion of patients prescribed high-intensity and moderate-intensity statins was 5,8%, and 94,2% According to the Ministry of Health guidelines, 3,8% of patients at high or very high cardiovascular risk were prescribed high-intensity statins. Among patients aged 40–75, 61% were treated with moderate-intensity statins, regardless of cardiovascular risk. Conclusion: Lipid-lowering treatment in newly diagnosed type 2 diabetes patients needs further improvement to align with current guidelines.